Request Info Medical Affairs Prescribing Information Important Safety Information Visit Patient Site

Elevating Patients’ Experience

Learn Why All Hizentra Patients Will Be Transitioned From Vials To Prefilled Syringes Learn more

For pediatric* and adult patients with primary humoral immunodeficiency

Proven. Personalized. Leader.

Hizentra PI branding image
Hizentra PI branding image
Proven icon

Proven
Efficacy & Tolerability

Review study results
Self-administration icon

Personalized
With Flexible Treatment Options

Explore individualized therapy
Leader icon

Leader
The #1 Ig Prescribed for PI1

Start patients on Hizentra

*Ages 2 and older.

Hizentra is indicated for the treatment of primary immune deficiency (PI) in adults and pediatric patients 2 years and older.

Insights from a CSL-sponsored Harris Poll survey†

Of 52 PI patients surveyed who have used both IVIg and SCIg, most preferred SCIg2

79% of people in the Harris Poll study preferred SCIg graphic

†In an online survey, 41 of 52 adults with PI who have used both IVIg and SCIg preferred SCIg.

Hizentra PI Patients 2

Enhancing patient experience and impacting lives

Hizentra offers greater flexibility to personalize treatment—addressing lifestyle burdens and clinical challenges associated with IVIg—to fit the lives of patients with PI.

See patient types Hizentra can help
Hizentra PI Patients 1

Enhancing patient experience and impacting lives

Hizentra offers greater flexibility to personalize treatment—addressing lifestyle burdens and clinical challenges associated with IVIg—to fit the lives of patients with PI.

See patient types Hizentra can help

Elevate your patient’s experience

Prescribe proven protection with a first and only for Ig—
Hizentra Prefilled Syringes

Discover the convenience
Hizentra prefilled syringes

Meet Annette,
a patient with PI who enjoys the convenience of Hizentra Prefilled Syringes

See how prefilled syringes can help your patients

Request more information about Hizentra

Get info and materials

Have additional questions?

Connect with CSL Behring Medical Affairs to find additional information and ask questions.

Visit Medical Affairs
References: 1. Data on File. Available from CSL Behring as DOF HIZ-005. 2. Data on File. Available from CSL Behring as DOF HIZ-013.

View information about Hizentra for:

PI

primary immunodeficiency

CIDP

chronic inflammatory demyelinating polyneuropathy


acuity
You are now leaving the current website.

Do you want to continue?

No Yes